Proof-of-concept in treating congenital disease before birth using CRISPR pre-natal gene editing

via Medical Xpress

CHOP/Penn Medicine Team Shows first example of base-editing tool to treat a disease in utero in animal models

For the first time, scientists have performed prenatal gene editing to prevent a lethal metabolic disorder in laboratory animals, offering the potential to treat human congenital diseases before birth. Published today in Nature Medicine, research from Children’s Hospital of Philadelphia (CHOP) and the Perelman School of Medicine at the University of Pennsylvania offers proof-of-concept for prenatal use of a sophisticated, low-toxicity tool that efficiently edits DNA building blocks in disease-causing genes.

Using both CRISPR-Cas9 and base editor 3 (BE3) gene-editing tools, the team reduced cholesterol levels in healthy mice treated in utero by targeting a gene that regulates those levels. They also used prenatal gene editing to improve liver function and prevent neonatal death in a subgroup of mice that had been engineered with a mutation causing the lethal liver disease hereditary tyrosinemia type 1 (HT1).

HT1 in humans usually appears during infancy, and it is often treatable with a medicine called nitisinone and a strict diet. However, when treatments fail, patients are at risk of liver failure or liver cancer. Prenatal treatment could open a door to disease prevention, for HT1 and potentially for other congenital disorders.

“Our ultimate goal is to translate the approach used in these proof-of-concept studies to treat severe diseases diagnosed early in pregnancy,” said study co-leader William H. Peranteau, MD, a pediatric and fetal surgeon in CHOP’s Center for Fetal Diagnosis and Treatment. “We hope to broaden this strategy to intervene prenatally in congenital diseases that currently have no effective treatment for most patients, and result in death or severe complications in infants.”

“We used base editing to turn off the effects of a disease-causing genetic mutation,” said study co-leader Kiran Musunuru, MD, PhD, MPH, an associate professor of Cardiovascular Medicine at Penn. “We also plan to use the same base-editing technique not just to disrupt a mutation’s effects, but to directly correct the mutation.” Musunuru is an expert in gene-editing technology and previously showed that it can be used to reduce cholesterol and fat levels in the blood, which could lead to the development of a “vaccination” to prevent cardiovascular disease.

In this study, the scientists used base editor 3 (BE3), which takes clustered regularly interspersed short palindromic repeats (CRISPR), joins it with a modified CRISPR-associated protein 9 to form a partially active version of the CRISPR-Cas 9 tool, and harnesses it as a homing device to carry an enzyme to a highly specific genetic location in the liver cells of fetal mice. The enzyme chemically modified the targeted genetic sequence, changing one type of DNA base to another. BE3 is potentially safer than CRISPR-Cas9, because it does not fully cut the DNA molecule and leave it vulnerable to unanticipated errors when the cut is repaired, as has been seen with the CRISPR-Cas9 tool.

After birth, the mice in the study carried stable amounts of edited liver cells for up to three months after the prenatal treatment, with no evidence of unwanted, off-target editing at other DNA sites. In the subgroup of the mice bioengineered to model HT1, BE3 improved liver function and preserved survival. The BE3-treated mice were also healthier than mice receiving nitisinone, the current first-line treatment for HT1 patients.

To deliver CRISPR-Cas9 and BE3, the scientists used adenovirus vectors, which have often been used in gene therapy experiments. Because previous gene therapy research has shown that adenovirus vectors may cause unintended and sometimes deleterious responses from the host’s immune system, the team is investigating alternate delivery methods such as lipid nanoparticles, which are less likely to stimulate unwanted immune responses.

A future direction for the team, in addition to using base editing to directly correct disease-causing mutations, will be to investigate its application to other diseases, including those based in organs beyond the liver.

“A significant amount of work needs to be done before prenatal gene editing can be translated to the clinic, including investigations into more clinically relevant delivery mechanisms and ensuring the safety of this approach,” said Peranteau, who added, “Nonetheless, we are excited about the potential of this approach to treat genetic diseases of the liver and other organs for which few therapeutic options exist.”

Learn more: Guided by CRISPR, Prenatal Gene Editing Shows Proof-of-Concept in Treating Congenital Disease before Birth

 

See Also

 

The Latest on: Prenatal gene editing

[google_news title=”” keyword=”prenatal gene editing” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]

via Google News

 

The Latest on: Prenatal gene editing
  • Simple New Strategy Improves Safety and Precision of CRISPR Gene Editing
    on May 25, 2024 at 4:02 pm

    KAUST researchers have improved CRISPR gene editing safety by reducing harmful DNA deletions and enhancing repair mechanisms, advancing towards safer genetic treatments. A simple and robust strategy ...

  • Unique gene editing drug could treat genetic blindness, but how it compares to existing therapies
    on May 23, 2024 at 7:00 am

    For the first time, genes can be edited after being injected into the eye to treat inherited blindness, but scientists in India prefer low cost & high efficacy solutions.

  • Best video editing apps in 2024
    on May 23, 2024 at 1:23 am

    The best video editing apps will allow you to produce high quality, professional feeling video on the fly using your smartphone or tablet. They can be extremely useful if you travel a lot and/or ...

  • A new gene-editing system tackles complex diseases
    on May 21, 2024 at 8:00 am

    An evolution in gene-editing To understand why MOBEs were created, we have to understand the limitations of the traditional gene-editing tool CRISPR-Cas9. CRISPR-Cas9 uses a guide RNA, which acts ...

  • Birth Defects News
    on May 20, 2024 at 5:01 pm

    Apr. 2, 2024 — Researchers have found that even low to moderate alcohol use by pregnant patients may contribute to subtle changes in their babies' prenatal ... YKT6 Gene Variants Cause a New ...

  • Average Prenatal Care Cost & How Health Insurance Covers It
    on May 20, 2024 at 7:04 am

    And special tests like an amniocentesis can cost more than $2,500. Women typically have 10 to 15 prenatal visits over the course of a normal pregnancy. If any complications arise, there may be even ...

  • How Gene Editing Therapies Could Go Beyond Rare Diseases
    on May 16, 2024 at 5:43 pm

    Earlier this year, a group of scientists in the Netherlands used the gene editing tool CRISPR to eliminate HIV from immune cells in the lab, an eye-catching approach that is forming the basis of ...

  • University of Pennsylvania gene-editing spinout iEcure hits the FDA trifecta
    on May 16, 2024 at 5:00 pm

    IEcure expects to begin its first human testing of a gene-editing therapy for a rare genetic disorder during the second half of this year. A gene-editing company spun out of the University of ...

  • Gene editing improves soybean yield
    on May 14, 2024 at 2:36 am

    Chinese researchers have developed new soybean breeding lines using gene editing, potentially boosting the yield and protein content of the critical crop. Soybeans are the world's leading source ...

via  Bing News

 

What's Your Reaction?
Don't Like it!
0
I Like it!
0
Scroll To Top